179 related articles for article (PubMed ID: 29713473)
1. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors.
Yang MX; Coates RF; Ambaye A; Cortright V; Mitchell JM; Buskey AM; Zubarik R; Liu JG; Ades S; Barry MM
Biomark Res; 2018; 6():15. PubMed ID: 29713473
[TBL] [Abstract][Full Text] [Related]
2. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
Srivastava A; Hornick JL
Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
[TBL] [Abstract][Full Text] [Related]
5. [Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs].
Gurevich LE; Proshchina AE; Voronkova IA; Ashevskaya VE; Korosteleva PA; Dolzhansky OV
Arkh Patol; 2019; 81(5):11-21. PubMed ID: 31626200
[TBL] [Abstract][Full Text] [Related]
6. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
Wang YC; Iezza G; Zuraek MB; Jablons DM; Theodore PR; Bergsland EK; Donner DB; Warren RS; Nakakura EK
J Surg Res; 2010 Sep; 163(1):47-51. PubMed ID: 20599218
[TBL] [Abstract][Full Text] [Related]
7. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
9. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
10. Liver Metastasis of Gastrointestinal Neuroendocrine Tumors: A Single Center Experience.
Geramizadeh B; Kashkooe A; Malekhosseini SA
Hepat Mon; 2016 May; 16(5):e37293. PubMed ID: 27330538
[TBL] [Abstract][Full Text] [Related]
11. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
13. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
[TBL] [Abstract][Full Text] [Related]
14. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors.
Barbareschi M; Roldo C; Zamboni G; Capelli P; Cavazza A; Macri E; Cangi MG; Chilosi M; Doglioni C
Am J Surg Pathol; 2004 Sep; 28(9):1169-76. PubMed ID: 15316316
[TBL] [Abstract][Full Text] [Related]
15. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.
Barbareschi M; Murer B; Colby TV; Chilosi M; Macri E; Loda M; Doglioni C
Am J Surg Pathol; 2003 Feb; 27(2):141-9. PubMed ID: 12548159
[TBL] [Abstract][Full Text] [Related]
16. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
[TBL] [Abstract][Full Text] [Related]
17. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.
Koo J; Zhou X; Moschiano E; De Peralta-Venturina M; Mertens RB; Dhall D
Endocr Pathol; 2013 Dec; 24(4):184-90. PubMed ID: 24037217
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
[TBL] [Abstract][Full Text] [Related]
19. Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2010; 54(3):277-82. PubMed ID: 20518411
[TBL] [Abstract][Full Text] [Related]
20. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
